424 related articles for article (PubMed ID: 33754211)
21. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety.
Yang R; Shi YY; Han XH; Liu S
Oncol Res Treat; 2021; 44(6):333-343. PubMed ID: 33975311
[TBL] [Abstract][Full Text] [Related]
23. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
[TBL] [Abstract][Full Text] [Related]
25. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
26. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.
Stover DG; Winer EP
Breast; 2015 Nov; 24 Suppl 2():S132-5. PubMed ID: 26255198
[TBL] [Abstract][Full Text] [Related]
27. qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
Zuo K; Yuan X; Liang X; Sun X; Liu S; Connell PP; Li X; Yang W
Breast Cancer Res Treat; 2022 Jan; 191(2):335-344. PubMed ID: 34797456
[TBL] [Abstract][Full Text] [Related]
28. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
29. Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer.
Valsecchi ME; Kimmey G; Bir A; Silbermins D
Rev Recent Clin Trials; 2015; 10(2):101-10. PubMed ID: 26104428
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
[TBL] [Abstract][Full Text] [Related]
31. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Mayer IA; Zhao F; Arteaga CL; Symmans WF; Park BH; Burnette BL; Tevaarwerk AJ; Garcia SF; Smith KL; Makower DF; Block M; Morley KA; Jani CR; Mescher C; Dewani SJ; Tawfik B; Flaum LE; Mayer EL; Sikov WM; Rodler ET; Wagner LI; DeMichele AM; Sparano JA; Wolff AC; Miller KD
J Clin Oncol; 2021 Aug; 39(23):2539-2551. PubMed ID: 34092112
[TBL] [Abstract][Full Text] [Related]
32. Assessing the role of platinum agents in aggressive breast cancers.
Sikov WM
Curr Oncol Rep; 2015 Feb; 17(2):3. PubMed ID: 25665554
[TBL] [Abstract][Full Text] [Related]
33. Do platinum salts fit all triple negative breast cancers?
Gerratana L; Fanotto V; Pelizzari G; Agostinetto E; Puglisi F
Cancer Treat Rev; 2016 Jul; 48():34-41. PubMed ID: 27343437
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis.
Li J; Shen G; Wang M; Huo X; Zhao F; Ren D; Zhao Y; Zhao J
Clin Exp Med; 2023 Sep; 23(5):1489-1499. PubMed ID: 36152119
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response.
Weng ZJ; Wu SX; Luo HS; Du ZS; Li XY; Lin JZ
Inquiry; 2021; 58():469580211056213. PubMed ID: 34806458
[TBL] [Abstract][Full Text] [Related]
36. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
37. Evolving treatment strategies for triple-negative breast cancer.
Telli M
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):652-4. PubMed ID: 25995421
[TBL] [Abstract][Full Text] [Related]
38. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
39. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
40. Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.
Chen Y; Wang X; Du F; Yue J; Si Y; Zhao X; Cui L; Zhang B; Bei T; Xu B; Yuan P
Cancer Biol Med; 2023 Mar; 20(2):155-68. PubMed ID: 36861447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
